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Absence of acquired copy number neutral loss of
heterozygosity (CN-LOH) of chromosome 7 in a series of 10
patients with Shwachman–Diamond syndrome
We report that acquired copy number neutral loss of hetero-
zygosity (CN-LOH) of chromosome 7 was not identified in a
series of 10 patients with Shwachman–Diamond syndrome
(SDS).
Shwachman–Diamond syndrome (Online Mendelian
Inheritance in Man reference 260400) is a rare autosomal
recessive disease first reported in 1964 (Bodian et al,1964;
Shwachman et al,1964) and characterized by exocrine pan-
creatic insufficiency, skeletal abnormalities and bone marrow
(BM) dysfunction with an increased risk to develop myelo-
dysplastic syndrome and/or acute myeloid leukaemia (MDS/
AML). Almost 90% of SDS cases are caused by two common
mutations, c. [183_184TA>CT] and c.[258 + 2T>C], in exon
2 of the SBDS gene, localized on chromosome 7. Clonal
chromosome anomalies are often found in the BM of SDS
patients; the most frequent are an isochromosome for long
arms of chromosome 7, i(7)(q10) and an interstitial deletion
of long arms of chromosome 20, del(20)(q11) (Maserati
et al, 2009).
An earlier study analysed BM DNA of eight cases with the
i(7)(q10) and demonstrated that all of them carried a double
dose of the c.[258 + 2T>C] (Minelli et al, 2009). This result
suggested that, as the c.[258 + 2T>C] mutation still allows
the production of some amount of normal protein (Austin
et al, 2005), this could contribute to the low incidence of
MDS/AML observed in this subset of SDS patients.
Recently, Parikh et al (2012) described acquired CN-LOH
for most of 7q in a patient with SDS, also showing that the
clone of BM cells with CN-LOH contained two copies of the
gene with the c.[258 + 2T>C] mutation. The presence of the
CN-LOH in BM cells mimics the presence of i(7)(q10): both
mechanisms produce a duplication of the c.[258 + 2T>C]
mutation, together with the probable associated positive
effects.
Parikh et al (2012) also outlined that the genetic variation
of the CN-LOH could provide an explanation for clonal
expansion of the affected haematopoietic progenitor cell.
Consequently, we investigated if, to provide the cell with
an extra copy of the c.[258 + 2T>C] mutation, this could be
a common mechanism in addition to the typical i(7)(q10)
frequently observed in BM from SDS patients. We collected
BM samples from 10 SDS patients in whom the cytogenetic
analysis demonstrated a normal karyotype (eight cases) or
the presence of the 20q deletion (two cases). The genotypes
were c.[258 + 2T>C]/[183_184TA>CT] in seven cases and
c.[258 + 2T>C]/[others] in three cases.
Morphological analysis of the BM aspirate, available for
six patients, showed normal or hypoplastic cellularity in
three, and normal or hyperplastic cellularity with minimal
decrease of erythropoiesis, megakaryopoiesis and myelopoie-
sis in the remaining three. These data are in keeping with the
karyotype-phenotype correlation discussed by Pressato et al
(2012).
Microsatellite analysis, performed as reported in Minelli
et al (2009), demonstrated a normal dosage between paternal
and maternal alleles, excluding the presence of uniparental
disomy related to chromosome 7, in all BM samples exam-
ined (Table I and Fig 1A). The method is able to identify the
presence of the chromosomal anomaly if it is present in at
least 20% of cells (Minelli et al, 2009).
To verify the reliability of the method, we sequenced exon
2 of the SBDS gene from the BM of two SDS patients with
50–70% cells with i(7)(q10) and, as expected, found that the
mutant peak (C) was higher than the wild-type peak (T)
(Fig 1B).
Exon 2 of the SBDS gene was then sequenced using BM
and peripheral blood samples and, in all cases analysed, the
mutant peak (C) and the wild-type peak (T) for the
c.[258 + 2T>C] mutation were exactly the same height in
both samples (Fig 1C) whereas Parikh et al (2012) observed
an higher peak for the mutated allele when BM and fibro-
blasts were compared.
Thus, no evidence for CN-LOH was found in any of the
patients studied. If the hypothesis that an increased level of
the c.[258 + 2T>C] mutation on a SDS background
(c.[183_184TA>CT]/c.[258 + 2T>C]) provides a selective
advantage, we would expect to identify cases in whom a
clone showing a (partial) loss of the c.[183_184TA>CT] or
an homozygous c.[258 + 2T>C] is present.
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Table I. Result of molecular and morphological analyses on bone marrow samples in 10 Shwachman–Diamond syndrome patients.
Case SBDS genotypes
Allelic ratio*
Bone marrow morphologyShort arm Long arm
1 [c.258 + 2T>C]/[c.183_184TA>CT] 125 (2) 127 (2) na
2 [c.258 + 2T>C]/[c.183_184TA>CT] 098 (2) 099 (2) a
3 [c.258 + 2T>C]/[c.183_184TA>CT] 096 (3) 0985 (3) na
4 [c.258 + 2T>C]/[c.183_184TA>CT] 094 (2) 106 (3) a
5 [c.258 + 2T>C]/[c.258 + 2T>C + 183_184TA>CT] 113 (3) 107 (3) c
6 [c.258 + 2T>C]/[c.183_184TA>CT] 098 (2) 09 (4) b
7 [c.258 + 2T>C]/[c.107delT] 101 (2) 095 (2) d
8 [c.258 + 2T>C]/[c.101A>T] 115 (2) 116 (5) c
9 [c.258 + 2T>C]/[c.183_184TA>CT] 086 (4) 092 (4) na
10 [c.258 + 2T>C]/[c.183_184TA>CT] 099 (3) 095 (3) na
na, not available.
*patient genotype is expressed as ratio between peak heights of chromosome 7 informative alleles of the short tandem repeat polymorphisms
analysed (the number of these is given in brackets).
Bone marrow morphology is reported as follows: a, hypoplastic cellularity and absence of megakaryocytes; b, normal/hypoplastic cellularity,
isolated megakaryocytes and limited dysmyelopoiesis (<10%); c, normal/hyperplastic cellularity, normal/few megakaryocytes and absence of
dysmyelopoiesis; d, normal cellularity and megakaryocytes, erythro-myeloid component sufficiently present.
(A) (B)
(C)
Fig 1. Examples of experimental investigations (A) Short tandem repeat polymorphisms analysis in three cases. (B) Chromatographs of the
c.[258 + 2T>C] mutation from bone marrow samples of two Shwachman–Diamond syndrome (SDS) patients with 50% (left) and 70% (right)
cells with i(7)(q10), the mutant peak (C) is higher than the wild-type peak (T) in both. (C) Chromatographs of the c.[258 + 2T>C] mutation
from peripheral blood (left) and bone marrow (right) samples from two of ten SDS patients analysed in the present study. The mutant peak (C)
and the wild-type peak (T) for the c.[258 + 2T>C] mutation were exactly the same height in both cases.
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Ofatumumab monotherapy in relapsed/refractory mantle cell
lymphoma – a phase II trial
Mantle cell lymphoma (MCL), an uncommon subtype of
non-Hodgkin lymphoma (NHL), is considered one of the
more aggressive lymphoid tumours. Despite the use of novel
treatment regimens, MCL remains incurable and the focus of
therapy is on the depth and duration of remission.
The chimeric CD20 monoclonal antibody rituximab is a
commonly used therapy in lymphoma and rituximab mono-
therapy shows some efficacy in MCL (Foran et al, 2000). It
has recently been shown to improve the overall survival in
MCL when added to combination chemotherapy, without
increasing treatment toxicity (Rule et al, 2011).
Ofatumumab is a fully human type 1 CD20 monoclonal
antibody that targets a novel epitope on the CD20 molecule
(Teeling et al, 2006). This allows closer binding to the cell
surface, which is thought to contribute to both its increased
ability to activate complement-dependent cytotoxicity (CDC)
and the longer off-rate compared to rituximab.
Ofatumumab has shown single agent activity in the treat-
ment of chronic lymphocytic leukaemia (CLL) (Coiffier et al,
2008) and relapsed/refractory follicular lymphoma (Hagen-
beek et al, 2008) with overall response rates of 44% and
42%, respectively. No dose-limiting toxicities occurred in
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